OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
SEC Seeks ISS Client Voting Records in Proxy Adviser Probe 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Milei Threatens Falkland Oil Firms With Sanctions 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Add as a preferred source on Google
NEWARK, Calif., Feb. 20, 2018 -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will release fourth quarter fiscal year 2017 financial results on Tuesday, February 27, 2018, after the close of markets. The Company will host a conference call beginning at 4:30 p.m. EST (1:30 p.m. PST) to discuss its results.
Participants can access the live webcast from the Investor Relations section of Depomed's website at http://www.depomed.com. Please access the website 15 minutes prior to the start of the call to download and install any necessary audio software. An archived webcast replay will be available on the Company's website for three months.
Audio Conference Call:
| U.S. Dial-in Number: | 1-844-839-0046 |
| International Dial-in Number: | 1-857-270-6032 |
| Conference ID: | 2157887 |
An archived webcast replay will be available on the Company's website for three months.
About Depomed
Depomed is a leading specialty pharmaceutical company committed to putting the Patient First in everything it does. Depomed is focused on enhancing the lives of patients, families, physicians, providers and payors through the commercialization of products in the areas of pain and neurology, and in the development of drugs in areas of unmet medical need. Depomed currently markets three medicines focused on neuropathic pain and migraine through its Neurology and Pain businesses and its emerging Specialty Business is focused on orphan drug indications and areas of unmet medical need. To learn more about Depomed, visit www.depomed.com.
INVESTOR AND MEDIA CONTACTS:
Christopher Keenan
VP, Investor Relations and Corporate Communications
510-744-8000
[email protected]
Daniel Peisert
VP, Business Development
[email protected]
